Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2021 Apr:290:114067.
doi: 10.1016/j.jviromet.2021.114067. Epub 2021 Jan 18.

Analytical performances of five SARS-CoV-2 whole-blood finger-stick IgG-IgM combined antibody rapid tests

Hélène Péré  1 , Ralph-Sydney Mboumba Bouassa  2 , Serge Tonen-Wolyec  3 , Isabelle Podglajen  4 , David Veyer  5 , Laurent Bélec  6
Affiliations
Comparative Study

Analytical performances of five SARS-CoV-2 whole-blood finger-stick IgG-IgM combined antibody rapid tests

Hélène Péré et al. J Virol Methods. 2021 Apr.

Abstract

Facing the ongoing pandemic caused by SARS-CoV-2, there is an urgent need for serological assays identifying individuals previously infected by coronavirus disease 2019 (COVID-19), including rapid diagnostic tests (RDTs). We herein compared five new CE-IVD-labeled commercially available SARS-CoV-2 whole-blood finger-stick IgG/IgM combined RDTs, in parallel according to the manufacturers' instructions, with two serum panels obtained from 48 patients with confirmed COVID-19 (panel I) and from a group of 52 patients randomly selected, for whom serum samples collected before the COVID-19 epidemic (from October 1 to November 30, 2019) were negative for SARS-CoV-2 IgG (panel II). We found a sensitivity of 95.8 %, 91.6 %, 92.3 %, 97.9 % and 91.4 %, and a specificity of 98.1 %, 86.5 %, 100 %, 98.1 % and 84.6 %, for BIOSYNEX COVID-19 BSS (IgG/IgM) (Biosynex Swiss SA, Freiburg, Switzerland), Humasis COVID-19 IgG/IgM Test (Humasis Co., Ltd., Gyneonggi, Republic of Korea), LYHER COVID-19 IgM/IgG Rapid Test (Medakit Ltd, Hong Kong, China), SIENNA™ COVID-19 (IgG/IgM) Rapid Test Cassette (Salofa Oy, Salo, Finland) and NG-BIOTECH COVID-19 (IgG/IgM) (NG-Biotech, Guipry, France), respectively. Commercially available SARS-CoV-2 IgG/IgM combined RDTs have a sufficient sensitivity for identifying individuals with past SARS-CoV-2 infection, but some RDTs may lack of specificity, with risk of false positivity mainly for the IgM band.

Keywords: Blood specimen; COVID-19; False positivity; IgG; IgM; Immunochromatography; Rapid diagnostic test; SARS-CoV-2; Sensitivity; Specificity.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest. The authors alone are responsible for the content and the writing of the paper.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Abduljalil J.M. Laboratory diagnosis of SARS-CoV-2: available approaches and limitations. New Microbes New Infect. 2020;36 - PMC - PubMed
    1. Aghokeng A.F., Mpoudi-Ngole E., Dimodi H., Atem-Tambe A., Tongo M., Butel C., Delaporte E., Peeters M. Inaccurate diagnosis of HIV-1 group M and O is a key challenge for ongoing universal access to antiretroviral treatment and HIV prevention in Cameroon. PLoS One. 2009;4:e7702. - PMC - PubMed
    1. Amanat F., Stadlbauer D., Strohmeier S., Nguyen T.H.O., Chromikova V., McMahon M., Jiang K., Arunkumar G.A., Jurczyszak D., Polanco J., Bermudez-Gonzalez M., Kleiner G., Aydillo T., Miorin L., Fierer D.S., Lugo L.A., Kojic E.M., Stoever J., Liu S.T.H., Cunningham-Rundles C., Felgner P.L., Moran T., García-Sastre A., Caplivski D., Cheng A.C., Kedzierska K., Vapalahti O., Hepojoki J.M., Simon V., Krammer F. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat. Med. 2020;26(7):1033–1036. - PMC - PubMed
    1. Bélec L., Péré H., Mboumba Bouassa R.S., Veyer D., Jenabian M.A. Potential pitfalls of routine SARS-CoV-2 serology for mass screening. J. Med. Virol. 2020 doi: 10.1002/jmv.26034. - DOI - PMC - PubMed
    1. Bouvet J.P., Dighiero G. From natural polyreactive autoantibodies to à la carte monoreactive antibodies to infectious agents: is it a small world after all? Infect. Immunol. 1998;66:1–4. - PMC - PubMed

Publication types